AR070014A1 - Derivados de piridina, su preparacion y uso - Google Patents

Derivados de piridina, su preparacion y uso

Info

Publication number
AR070014A1
AR070014A1 ARP080103463A ARP080103463A AR070014A1 AR 070014 A1 AR070014 A1 AR 070014A1 AR P080103463 A ARP080103463 A AR P080103463A AR P080103463 A ARP080103463 A AR P080103463A AR 070014 A1 AR070014 A1 AR 070014A1
Authority
AR
Argentina
Prior art keywords
aryl
alkyl
heterocyclyl
alkenyl
alkoxy
Prior art date
Application number
ARP080103463A
Other languages
English (en)
Inventor
Mandar Ramesh Bhonde
Nilambari Nilkanth Yewalkar
Maggie Joyce Rathos
Amol Arun Padgaonkar
Sapna Parikh
Nilesh Madhukar Dagia
Kalpana Sanjay Joshi
Sanjay Kumar
Vijaykumar Deore
Asha Adrian Kulkarni-Almeida
Original Assignee
Piramal Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Life Sciences Ltd filed Critical Piramal Life Sciences Ltd
Publication of AR070014A1 publication Critical patent/AR070014A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

También se revelan procesos para la preparacion de estos derivados, y su uso en la elaboracion de composiciones farmacéuticas para el tratamiento del cáncer y de la inflamacion. Reivindicacion 1: Un compuesto de la formula (1) en donde, A y B se seleccionan independientemente de carbono y nitrogeno; siempre y cuando por lo menos uno de entre A y B sea nitrogeno; R1 se selecciona de hidrogeno, alquilo, alquenilo, alquinilo, acilo, hidroxi, alcoxi, arilo, y ariloxi, o está ausente; R2 se selecciona de hidrogeno, alquilo, alquenilo, alquinilo, acilo, hidroxi, alcoxi, arilo, y ariloxi; R3 se selecciona de hidrogeno, alquilo, alquenilo, alquinilo, acilo, hidroxi, alcoxi, arilo, ariloxi, y -O-R6; o R2 y R3 juntos con el átomo N al cual se encuentran anexos forman un heterociclo de 5 miembros que tiene por lo menos un heteroátomo adicional seleccionado de O, N y S; en donde el heterociclo podrá estar no sustituido o sustituido; o R2 y R3 junto con el átomo N al cual se encuentran anexos forman un heterociclo de 6 o 7 miembros, teniendo opcionalmente uno o más heteroátomos adicionales seleccionados de O, N y S; en donde el heterociclo podrá estar no sustituido o sustituido; R4 y R5 se seleccionan independientemente de hidrogeno, alquilo, haloalquilo, aralquilo, alquenilo, alquinilo, arilo, heterociclilo, cicloalquilo, -O-R6, y -C(O)-T-Q; R6 se selecciona de alquenilo y alquinilo; en donde el alquenilo y el alquinilo podrán estar no sustituidos o sustituidos; T se selecciona de -(CR7R8)n- y -C(R7R8)C(O)-, donde n es un entero de 0 a 5; R7 y R8 se seleccionan independientemente de hidrogeno, alquilo, haloalquilo, cicloalquilo, alquenilo, halogeno, hidroxi, alcoxi, ciano, nitro, arilo, y heterociclilo; y Q se selecciona de hidrogeno, hidroxi, halogeno, ciano, nitro, alquilo, haloalquilo, alcoxi, cicloalquilo, heterociclilo, y arilo; en donde R1, R2, R3, R4, R5, T, R7, R8 y Q son: alquilo y cicloalquilo no sustituido o sustituido con por lo menos un grupo seleccionado de halogeno, hidroxi, carboxi, acetoxi, amino, cicloalquilo, alcoxi, ariloxi, alcoxicarbonilo, aminocarbonilo, aminoarilo, arilo, aralquilo, y heterociclilo; arilo no sustituido o sustituido con por lo menos un grupo seleccionado de halogeno, nitro, alquilo, haloalquilo, alcoxi, amino, heteroarilalquilo, heterociclilo, arilo, y aralquilo; y heterociclilo no sustituido o sustituido con por lo menos un grupo seleccionado de halogeno, hidroxi, alcoxi, oxo, alquilo, haloalquilo, alquenilo, alquinilo, heterociclilo, ariloxi, cicloalquilo, cicloalquilalquilo, acilo, aciloxi, amino, aminoalquilo, hidroxialquilo, heterociclilalquilo, heteroarilalquilo, aralquilo, alquilaminoalquilo, formilo, alquilcarbonilo, arilcarbonilo, arilo, alquilamino, alquilheteroarilamino, alcoxicarbonilo, ariloxicarbonilo, -COOH, -C(O)-O-R6, y -O-R6; con la salvedad de que: cuando R1 se selecciona de hidrogeno, alquilo, alquenilo, alquinilo, acilo, hidroxi, alcoxi, arilo, y ariloxi, entonces por lo menos uno de entre R4 y R5 es -C(O)-T-Q; con la otra salvedad de que: cuando Q se selecciona de cicloalquilo, heterociclilo, y arilo, entonces R2 y R3 junto con el átomo N al cual se encuentran anexos forman un heterociclo de 5 miembros que tiene por lo menos un heteroátomo adicional seleccionado de O, N y S; en donde el heterociclo podrá estar no sustituido o sustituido; o R2 y R3 junto con el átomo N al cual se encuentran anexo forman un heterociclo de 6 o 7 miembros, que tiene opcionalmente uno o más heteroátomos adicionales seleccionados de O, N y S; en donde el heterociclo podrá estar no sustituido o sustituido; y las formas estereoisoméricas y tautoméricas y mezclas de las misma en todos sus índices, sales farmacéuticamente aceptables, solvatos farmacéuticamente aceptables, polimorfos farmacéuticamente aceptables y prodrogas de los mismos.
ARP080103463A 2007-08-07 2008-08-07 Derivados de piridina, su preparacion y uso AR070014A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95443707P 2007-08-07 2007-08-07

Publications (1)

Publication Number Publication Date
AR070014A1 true AR070014A1 (es) 2010-03-10

Family

ID=40083721

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103463A AR070014A1 (es) 2007-08-07 2008-08-07 Derivados de piridina, su preparacion y uso

Country Status (4)

Country Link
US (1) US8314103B2 (es)
AR (1) AR070014A1 (es)
TW (1) TW200908984A (es)
WO (1) WO2009019656A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
EP4095127A1 (en) 2006-06-26 2022-11-30 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
CA2774046C (en) 2009-11-06 2014-01-21 Aerpio Therapeutics Inc. Compositions comprising n-benzyl or n-sulfonylaryl-3-hydroxypyridin-2-(1h)-ones and their use for treating colitis
US9315491B2 (en) 2009-12-28 2016-04-19 Development Center For Biotechnology Pyrimidine compounds as mTOR and PI3K inhibitors
WO2011080568A2 (en) * 2009-12-28 2011-07-07 Development Center For Biotechnology Novel pyrimidine compounds as mtor and p13k inhibitors
WO2011130908A1 (en) * 2010-04-21 2011-10-27 Merck Sharp & Dohme Corp. Substituted pyrimidines
WO2012082765A2 (en) * 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
CN103270026A (zh) * 2010-12-21 2013-08-28 诺瓦提斯公司 作为vps34抑制剂的联-杂芳基化合物
NO2686520T3 (es) 2011-06-06 2018-03-17
CN103717214A (zh) 2011-06-06 2014-04-09 阿克比治疗有限公司 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物
WO2013008162A1 (en) 2011-07-08 2013-01-17 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
WO2013066835A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013080120A1 (en) 2011-11-28 2013-06-06 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
EA029473B1 (ru) 2011-12-15 2018-03-30 Новартис Аг Применение ингибиторов pi3k для лечения острой и церебральной малярии
BR112015031027A2 (pt) 2013-06-13 2017-08-29 Akebia Therapeutics Inc Uso de um composto, método in vitro, composição farmacêutica e forma de dosagem única
AR097631A1 (es) * 2013-09-16 2016-04-06 Bayer Pharma AG Trifluorometilpirimidinonas sustituidas con heterociclos y sus usos
MX2021001169A (es) 2013-11-15 2023-02-10 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
EP3730590A1 (de) * 2014-03-10 2020-10-28 Merck Patent GmbH Flüssigkristalline medien mit homöotroper ausrichtung
JP2017114765A (ja) * 2014-04-25 2017-06-29 大正製薬株式会社 トリアゾリルで置換されたヘテロアリール化合物
WO2016113205A1 (de) 2015-01-13 2016-07-21 Bayer Pharma Aktiengesellschaft Substituierte pentafluorethylpyrimidinone und ihre verwendung
JP6693425B2 (ja) * 2015-01-14 2020-05-13 Jnc株式会社 重合性基を有する化合物、液晶組成物および液晶表示素子
BR112017015852A2 (pt) 2015-01-23 2018-03-27 Akebia Therapeutics Inc forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
IL292262B2 (en) 2015-04-01 2024-02-01 Akebia Therapeutics Inc Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid
CN107849457B (zh) * 2015-07-23 2021-11-30 捷恩智株式会社 液晶组合物及液晶显示元件
US10492494B2 (en) 2015-11-13 2019-12-03 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US20180354920A1 (en) 2015-11-13 2018-12-13 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
AR106679A1 (es) 2015-11-13 2018-02-07 Basf Se Oxadiazoles sustituidos para combatir hongos fitopatógenos
JP2018537457A (ja) 2015-11-19 2018-12-20 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 植物病原菌を駆除するための置換オキサジアゾール
US10986839B2 (en) 2016-04-11 2021-04-27 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
CN116903526A (zh) * 2017-08-23 2023-10-20 思普瑞特生物科学公司 吡啶基吡啶酮化合物
US11434249B1 (en) 2018-01-02 2022-09-06 Seal Rock Therapeutics, Inc. ASK1 inhibitor compounds and uses thereof
MX2020011845A (es) 2018-05-09 2021-01-15 Akebia Therapeutics Inc Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
CN109678852B (zh) * 2018-12-20 2022-04-19 南京中医药大学 6-氧代六氢嘧啶衍生物、其制备方法及制药应用
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
UY39854A (es) 2021-07-15 2022-11-30 Kumiai Chemical Industry Co Derivado de formamida y agente de control hortícola y agrícola para el control de enfermedades de la

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9300433A (es) 1992-01-28 1994-07-29 Kirin Brewery Compuestos de piridincarboximidamina y composiciones farmaceuticas que los contienen.
HUP0400179A3 (en) * 2001-06-12 2004-10-28 Neurogen Corp Branford 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines, their use and pharmaceutical compositions containing them
EP1270551A1 (en) 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Urea derivatives with antiproteolytic activity
WO2004048365A1 (en) 2002-11-21 2004-06-10 Chiron Corporation 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050119243A1 (en) 2003-11-07 2005-06-02 Harris Wayne B. HIF-1 inhibitors and methods of use thereof
UY29300A1 (es) 2004-12-22 2006-07-31 Astrazeneca Ab Compuestos quimicos
WO2006094292A2 (en) 2005-03-02 2006-09-08 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
AU2008213808B2 (en) * 2007-02-06 2011-11-10 Novartis Ag PI 3-kinase inhibitors and methods of their use

Also Published As

Publication number Publication date
TW200908984A (en) 2009-03-01
WO2009019656A1 (en) 2009-02-12
US8314103B2 (en) 2012-11-20
US20110077252A1 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
AR070014A1 (es) Derivados de piridina, su preparacion y uso
AR073498A1 (es) Derivados de tieno [2-3-d] pirimidin
AR069435A1 (es) Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
CL2016002942A1 (es) Nuevos derivados de pirazolina pirimidina y su uso como inhibidores de malt1
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
PE20181024A1 (es) Derivados de ciclohexano sustituido con amido
CO5200848A1 (es) Derivados de 3(5)-ureido-pirazol, proceso para su prepa- racion y su utilizacion como agentes antitumorales
UY28578A1 (es) Derivados de amida
AR059895A1 (es) Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos
AR061371A1 (es) Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas.
AR080865A1 (es) Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
AR054081A1 (es) Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas
AR082826A2 (es) Inhibidores heterociclicos de mek, composiciones farmaceuticas que los contienen, usos, y metodos de preparacion de los mismos
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
CL2014003181A1 (es) Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas.
AR048495A1 (es) Benzoil amino heterociclicos, utiles para el tratamiento de enfermadades intermediadas por glk
AR043111A1 (es) Derivados monoacilados de o-fenilendiaminas
AR067443A1 (es) Derivados heterociclicos de n-benziloxazolidinonas potenciadores de receptores de glutamato mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos del sistema nervioso central
ES2653265T3 (es) Morfinanos sustituidos y el uso de éstos
ES2684517T3 (es) Compuestos de heterociclilo como inhibidores de MEK
AR054365A1 (es) Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos.
ECSP10010506A (es) Derivados de 1-heterociclilo-1,5-dihidro-pirazol [3,4-D] pirimidino-4-ona y su uso como inhibidores de PDE9A.
AR047969A1 (es) Pirazolotriazinas como inhibidores de quinasa
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso

Legal Events

Date Code Title Description
FB Suspension of granting procedure